191 related articles for article (PubMed ID: 9816323)
21. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
[TBL] [Abstract][Full Text] [Related]
23. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Bao HY; Fang WJ; Zhang XC; Shi GM; Huang S; Yu LF; Chen J; Mou HB; Deng J; Shen P; Xu N
Cancer Chemother Pharmacol; 2011 Jan; 67(1):147-52. PubMed ID: 20221830
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
Schilsky RL; Janisch L; Berezin F; Mick R; Vogelzang NJ; Ratain MJ
Cancer Res; 1993 Mar; 53(6):1293-6. PubMed ID: 7680282
[TBL] [Abstract][Full Text] [Related]
26. Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.
O'Connell MJ; Klaassen DJ; Everson LK; Cullinan S; Wieand HS
NCI Monogr; 1987; (5):185-8. PubMed ID: 3501540
[TBL] [Abstract][Full Text] [Related]
27. Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report.
Kronawitter U; Kemeny NE; Blumgart L
Cancer; 1997 Aug; 80(4):656-60. PubMed ID: 9264347
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of docetaxel, Cisplatin, 5-Fluorouracil and leucovorin.
Mulcahy MF; Loehrer PJ; Meropol NJ; Rademaker AW; Benson Iii AB
Oncology; 2005; 68(4-6):479-84. PubMed ID: 16020978
[TBL] [Abstract][Full Text] [Related]
29. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Soveri LM; Hermunen K; de Gramont A; Poussa T; Quinaux E; Bono P; André T; Österlund P
Eur J Cancer; 2014 Nov; 50(17):2966-74. PubMed ID: 25266443
[TBL] [Abstract][Full Text] [Related]
30. A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Oldenhuis CN; Loos WJ; Esteves B; van Doorn L; Cotreau MM; Strahs AL; den Hollander MW; Gietema JA; de Vries EG; Eskens FA
Clin Colorectal Cancer; 2015 Mar; 14(1):18-24.e1. PubMed ID: 25591799
[TBL] [Abstract][Full Text] [Related]
31. A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Stöger H; Bauernhofer T; Schmid M; Ploner F; Moser R; Derstvenscheg E; Steindorfer P; Wilders-Truschnig M; Kuss I; Samonigg H
Cancer Chemother Pharmacol; 1994; 35(2):174-8. PubMed ID: 7987997
[TBL] [Abstract][Full Text] [Related]
32. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
[TBL] [Abstract][Full Text] [Related]
33. The French experience with infusional 5-fluorouracil in advanced colorectal cancer.
de Gramont A; Louvet C; Krulik M
J Infus Chemother; 1996; 6(3):133-6. PubMed ID: 9229324
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
Zaniboni A
J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Goldberg RM; Reid JM; Ames MM; Sloan JA; Rubin J; Erlichman C; Kuffel MJ; Fitch TR
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2363-70. PubMed ID: 9815635
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
O'Dwyer PJ; Cornfeld MJ; Peter R; Comis RL
Cancer Chemother Pharmacol; 1990; 27(2):131-4. PubMed ID: 2249328
[TBL] [Abstract][Full Text] [Related]
37. Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens.
Tsavaris N; Kosmas C; Polyzos A; Genatas K; Vadiaka M; Paliaros P; Dimitrakopoulos A; Rokana S; Karatzas G; Vachiotis P; Fotiadis K
Tumori; 2001; 87(5):303-7. PubMed ID: 11765178
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients.
Leonardi V; Meli M; Palmeri S; Russo A; Rini GB; Peralta S; Rausa L
J Chemother; 1995 Apr; 7(2):160-6. PubMed ID: 7545224
[TBL] [Abstract][Full Text] [Related]
39. Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group.
Colucci G; Giotta F; Gebbia V; Riccardi F; Pezzella G; Durini E; Caruso M; Romito S; Gebbia N
Anticancer Drugs; 1997 Mar; 8(3):257-64. PubMed ID: 9095330
[TBL] [Abstract][Full Text] [Related]
40. Mitoxantrone, fluorouracil plus L-leucovorin, and vinorelbine in pretreated advanced breast cancer.
Colleoni M; Nelli P; Gaion F; Sgarbossa G; Manente P
Oncology; 1995; 52(6):435-8. PubMed ID: 7478426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]